检索结果-南通市图书馆

Review on application of phase change materials in asphalt pavement

Journal of Traffic and Transportation Engineering(English Edition) 2023年第2期10卷 185-229页

作者： Xiaoqing Wang Biao Ma Siqi Li Wei Si Kun Wei Hongfei Zhang Xueyan Zhou Yunfeng Fang xingxiang kang Wenshuo Shi Key Laboratory for Special Area Highway Engineering of Ministry of Education Chang’an UniversityXi’an 710064China School of Modern Post Xi’an University of Posts&TelecommunicationsXi’an 710064China School of Transportation Southeast UniversityNanjing 211189China Dongtai Highway Development Center Dongtai 224200China

Phase change materials(PCMs)can regulate the temperature in asphalt pavement and minimize temperature-related problems,such as rutting and thermal cracking,because of their ability to store and release latent *** PCMs can also enable additional road surface functions,such as snow melting ability,freeze-thaw cycle resistance,and heat island *** functions are helpful in achieving intelligent,green,and sustainable transportation *** the research on PCMs for asphalt pavement has been carried out for more than 10 years,a systematic material system and mature application technology have not yet been *** main reasons for restricting the development of this technology include the lack of suitability between the PCMs and asphalt pavement,the quantitative characterization of phase change temperature regulation property,and the evaluation of the effect of phase change energy storage on improving pavement *** the published review has made a comprehensive summary of the existing research,it has yet to identify the key restricting the development of this technology and carry out a review and discussion based on *** grasp the development status of the application of PCMs in asphalt pavement,sort out the development needs and break through the technical barriers,this study systematically summarizes the preparation and performance of PCMs for asphalt pavement,compares the performance and evaluation methods of asphalt mixtures with different PCMs,and summarizes the numerical simulation methods of phase change asphalt ***,this study presents potential approaches to address critical technical issues and discusses possible future research.

关键词： Asphalt mixture Phase change material Road performance Thermal performance Thermoregulation

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

级配碎石变形特性的试验

引用

江苏大学学报（自然科学版） 2022年第1期43卷 101-106页

作者：康兴祥马骉李宁司伟王小庆长安大学特殊地区公路工程教育部重点实验室陕西西安710064 西安建筑科技大学土木工程学院陕西西安710055

针对级配组成、水的质量分数及密实度等3个因素对级配碎石的影响,采用精密非粘结材料分析仪(precision unbound materials analyzer,PUMA)试验和重复荷载加州承载比(California bearing ratio,CBR)试验方法,研究了级配碎石的抗变形能力... 详细信息

针对级配组成、水的质量分数及密实度等3个因素对级配碎石的影响,采用精密非粘结材料分析仪(precision unbound materials analyzer,PUMA)试验和重复荷载加州承载比(California bearing ratio,CBR)试验方法,研究了级配碎石的抗变形能力.借助累积塑性变形和弹性形变指标,对比分析2种试验异同点.试验结果表明:在荷载作用前期,级配碎石材料抗变形能力受荷载作用的影响显著,随着荷载作用次数不断增大,其影响逐渐减小;PUMA试验与重复荷载CBR试验累积塑性变形结果基本一致,而弹性应变指标存在差异;PUMA试验中弹性应变受级配碎石材料上述3个因素共同影响,重复荷载CBR试验中弹性应变受级配碎石密实度的影响;对级配碎石变形特性精度要求较低时,可选择重复荷载CBR试验研究级配碎石材料变形特性;由于PUMA设备和加载均接近实际工况,因此对级配碎石变形特性精度要求较高时,推荐选用PUMA试验测试方法.

关键词：级配碎石抗变形能力 PUMA试验重复荷载CBR试验对比分析

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

单组分环氧树脂用潜伏型固化剂研究进展

引用

中国塑料 2021年第12期35卷 154-165页

作者：方云峰马骉王小庆康兴祥汤宇婷长安大学公路学院特殊地区公路工程重点实验室西安710064 河海大学地球科学与工程学院南京211100

对国内外有关单组分环氧树脂用固化剂进行了梳理,介绍了潜伏型单组分环氧树脂用固化剂(热致型、湿致型、光致型以及微胶囊型),并对其制备合成方法及固化机理进行详细的综述,指出了单组分环氧树脂用固化剂所存在的问题,并明确未来的研究... 详细信息

对国内外有关单组分环氧树脂用固化剂进行了梳理,介绍了潜伏型单组分环氧树脂用固化剂(热致型、湿致型、光致型以及微胶囊型),并对其制备合成方法及固化机理进行详细的综述,指出了单组分环氧树脂用固化剂所存在的问题,并明确未来的研究思路。

关键词：单组分环氧树脂潜伏型固化剂微胶囊技术制备方法固化机理

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

高分子橡胶对浅色沥青结合料性能影响研究

引用

交通节能与环保 2019年第2期15卷 83-87页

作者：马小军陈修乐康兴祥武红娟西北民族大学土木工程学院甘肃兰州730124 不详

本研究通过聚合物物理共混法将石油树脂、苯乙烯-丁二烯-苯乙烯嵌段共聚物(SBS)和丁苯橡胶(SBR)等高分子橡胶加入到芳烃油中,利用高速剪切仪制备出均一的浅色沥青结合料。采用正交法设计试验方案,改变各组份掺量,研究SBS、SBR、石油树... 详细信息

本研究通过聚合物物理共混法将石油树脂、苯乙烯-丁二烯-苯乙烯嵌段共聚物(SBS)和丁苯橡胶(SBR)等高分子橡胶加入到芳烃油中,利用高速剪切仪制备出均一的浅色沥青结合料。采用正交法设计试验方案,改变各组份掺量,研究SBS、SBR、石油树脂对浅色沥青结合料针入度、软化点、延度三大指标的变化规律,从而确定各组份的合理掺量范围,并检测浅色沥青结合料短期老化性能。试验结果表明:通过浅色沥青结合料与其他沥青的对比分析,浅色沥青结合料的性能均有所提高,为后续彩色沥青结合料研究提供了理论依据。

关键词：浅色沥青结合料 SBS SBR 石油树脂

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19

引用

Signal Transduction and Targeted Therapy 2022年第5期7卷 1627-1633页

作者： Bo Gong Lulin Huang Yongquan He Wen Xie Yi Yin Yi Shi Jialing Xiao Ling Zhong Yi Zhang Zhilin Jiang Fang Hao Yu Zhou Huan Li Li Jiang xingxiang Yang Xiangrong Song Yan kang Lin Tuo Yi Huang Ping Shuai Yuping Liu Fang Zheng Zhenglin Yang Department of Health Management Sichuan Academy of Medical Sciences&Sichuan Provincial People’s HospitalUniversity of Electronic Science and Technology of ChinaChengduSichuanChina Sichuan Provincial Key Laboratory for Human Disease Gene Study Center for Medical GeneticsDepartment of laboratory medicineSichuan Academy of Medical Sciences&Sichuan Provincial People’s HospitalUniversity of Electronic Science and Technology of ChinaChengduSichuanChina Research Unit for Blindness Prevention of Chinese Academy of Medical Sciences(2019RU026) Sichuan Academy of Medical Sciences&Sichuan Provincial People’s HospitalUniversity of Electronic Science and Technology of ChinaChengduSichuanChina Institute of Chengdu Biology Sichuan Translational Medicine HospitalChinese Academy of SciencesChengduSichuanChina Center for Gene Diagnosis&Department of Laboratory Medicine Zhongnan Hospital of Wuhan UniversityWuhanChina Department of Laboratory Medicine Wuhan Leishenshan HospitalWuhanHubeiChina Infectious Disease Department Sichuan Provincial People’s HospitalUniversity of Electronic Science and Technology of ChinaChengdu 610041China Department of Critical Care Medicine Frontiers Science Center for Disease-related Molecular NetworkState Key Laboratory of BiotherapyWest China HospitalSichuan UniversityChengduChina

Critical coronavirus disease 2019(COVID-19)is associated with high mortality and potential genetic factors have been reported to be involved in the development of critical *** performed a genome-wide association study to identify the genetic factors responsible for developing critical COVID-19.632 critical patients with COVID-19 and 3021 healthy controls from the Chinese population were ***,we identified a genome-wide significant difference of IL-6 rs2069837(p=9.73×10^(−15),OR=0.41)between 437 critical patients with COVID-19 and 2551 normal controls in the discovery cohort.

关键词： protective patients mortality

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and Safety of All-oral,12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients:Results from a Phase 2/3 Clinical Trial in China

引用

Journal of Clinical and Translational Hepatology 2019年第3期7卷 213-220页

作者： Xiaoyuan Xu Bo Feng Yujuan Guan Sujun Zheng Jifang Sheng xingxiang Yang Yuanji Ma Yan Huang Yi kang Xiaofeng Wen Jun Li Youwen Tan Qing He Qing Xie Maorong Wang Ping An Guozhong Gong Huimin Liu Qin Ning Rui Hua Bo Ning Wen Xie Jiming Zhang Wenxiang Huang Yongfeng Yang Minghua Lin Yingren Zhao Yanhong Yu Jidong Jia Dongliang Yang Liang Chen Yinong Ye Yuemin Nan Zuojiong Gong Quan Zhang Peng Hu Fusheng Wang Yongguo Li Dongliang Li Zhansheng Jia Jinlin Hou Chengwei Chen Jinzi JWu Lai Wei Peking University First Hospital BeijingChina Peking University People's Hospital BeijingChina Guangzhou Eighth People's Hospital GuangzhouChina Beijing YouAn Hospital Capital Medical UniversityBeijingChina The First Affiliated Hospital of Medical School of Zhejiang University HangzhouChina Sichuan Provincial People's Hospital ChengduChina West China Hospital Sichuan UniversityChengduChina Xiangya Hospital Central South UniversityChangshaChina Henan Provincial People's Hospital ZhengzhouChina Liuzhou People's Hospital LiuzhouChina Jiangsu Province Hospital NanjingChina Zhenjiang No.3 People's Hospital ZhenjiangChina The Third People's Hospital of Shenzhen ShenzhenChina Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghaiChina People's Liberation Army Bayi Hospital NanjingChina Shenyang Sixth People's Hospital ShenyangChina The 2nd Xiangya Hospital of Central South University ChangshaChina Xixi Hospital of Hangzhou HangzhouChina Tongji Medical College of Huazhong University of Science&Technology WuhanChina The First Hospital of Jilin University ChangchunChina Baoji Center Hospital BaojiChina Beijing Ditan Hospital BeijingChina Huashan Hospital Affiliated to Fudan University ShanghaiChina Chongqing Medical University No.1 Affiliated Hospital ChongqingChina The Second Hospital of Nanjing NanjingChina Fujian Fuzhou Municipal Infectious Disease Hospital FuzhouChina No.1 Affiliated Hospital of Xi'an Jiaotong University Xi'anChina The First Affiliated Hospital of Guangxi Medical University NanningChina Beijing Friendship Hospital Capital Medical UniversityBeijingChina Wuhan Union Hospital WuhanChina Shanghai Public Health Clinical Center ShanghaiChina Foshan No.1 People's Hospital FoshanChina The Third Hospital of Hebei Medical University ShijiazhuangChina Wuhan University Renmin Hospital WuhanChina The Affiliated Hospital of Guizhou Medical University GuiyangChina The Second Affiliated Hospital of Chongqing Medical University ChongqingChina PLA 302 Hospital Be

Background and Aims:Ravidasvir(RDV)is a new generation pangenotypic hepatitis C virus(HCV)NS5A inhibitor,with high barrier to baseline resistance-associated *** is the first phase 2/3 study conducted in China's Mainland confirming the efficacy and safety of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks in treatment-naive noncirrhotic patients with genotype 1 infection in a large ***:In this multicenter,randomized,doubleblinded,placebo-controlled phase 2/3 trial(NCT03362814),we enrolled 424 treatment-nafve,noncirrhotic adult HCV genotype 1 *** patients were randomized at 3∶1 ratio to receive a combination of RDV 200mg once daily plus ritonavir-boosted danoprevir 100mg/100mg twice daily and oral ribavirin 1000/1200mg/day(body weight<75/≥75 kg)(n=318)or placebo(n=106)for 12 *** primary end-point was the rate of sustained virologic response 12 weeks after the end of treatment,and the safety was evaluated and compared between treatment and placebo ***:The overall rate of sustained virological response at 12 weeks after treatment is 99%(306/309,95%,CI:97%-100%)under per protocol set *** patients harboring baseline NS5A resistance-associated species in the treatment group(76/76,per protocol set)achieved sustained virological response at 12 weeks after *** treatment-related serious adverse events were *** abnormalities showed mild or moderate severity(grade 1 and grade 2)in liver function ***:In treatment-na(i)ve,noncirrhotic HCV Chinese patients infected with HCV genotype 1,all-oral regimen of RDV+ritonavir-boosted danoprevir+ribavirin for 12 weeks was highly efficacious,safe,and well tolerated.

关键词： Ravidasvir Danoprevir HCV SVR Treatment-naive Noncirrhotic GT1

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

引用

The Innovation 2024年第6期5卷 100-116页

作者： Wenxian Wang Bin Lian Chunwei Xu Qian Wang Ziming Li Nan Zheng Aijun Liu Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Lili Mao Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Jian Feng Rui Ge Enyong Dai Yu Han Weiwei Pan Fei Pang Xin Huang Meizhen Hu Qing Hao Kai Wang Fan Wu Binbin Song Bingwei Xu Liping Wang Youcai Zhu Li Lin Yanru Xie Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zhen Wang Bin Wan Donglai Lv Shengjie Yang Jin kang Jiatao Zhang Chao Zhang Wenfeng Li Jianfei Fu Lizhi Wu Shijie Lan Juanjuan Ou Lin Shi Zhanqiang Zhai Yina Wang Bihui Li Zhang Zhang Ke Wang Xuelei Ma Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Huijuan Wang Gu Jin Guansong Wang Jiandong Wang Hubing Shi Meiyu Fang Yong Fang Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Yong Song Zhengbo Song Wenfeng Fang Yuanzhi Lu Lu Si Department of Chemotherapy Chinese Academy of Sciences University Cancer Hospital(Zhejiang Cancer Hospital)HangzhouZhejiang 310022P.R.China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Melanoma and SarcomaPeking University Cancer Hospital&InstituteBeijing 100142P.R.China Institute of Cancer and Basic Medicine(ICBM) Chinese Academy of SciencesHangzhouZhejiang 310022P.R.China Department of Respiratory Medicine Affiliated Jinling HospitalMedical School of Nanjing UniversityNanjingJiangsu 210002P.R.China Department of Respiratory Medicine Affiliated Hospital of Nanjing University of Chinese MedicineJiangsu Province Hospital of Chinese MedicineNanjingJiangsu 210029P.R.China Department of Shanghai Lung Cancer Center Shanghai Chest HospitalShanghai Jiao Tong UniversityShanghai 200030P.R.China Beijing Key Laboratory of Mental Disorders National Clinical Research Center for Mental Disorders&National Center for Mental DisordersBeijing Anding HospitalCapital Medical UniversityBeijing 200030China Advanced Innovation Center for Human Brain Protection Capital Medical UniversityBeijing 200030China Senior Department of Pathology the 7th Medical Center of PLA General HospitalBeijing 100700P.R.China Department of Cancer Molecular Diagnostics Core Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China Guangdong Lung Cancer Institute Guangdong Provincial Laboratory of Translational Medicine in Lung CancerGuangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesSchool of MedicineGuangzhouGuangdong 510080P.R.China State Key Laboratory of Molecular Oncology Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021P.R.China Department of Medical Oncology Lung Cancer and Gastrointestinal UnitHunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School

The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and *** the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of *** mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among *** is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors.

关键词： BRAF diagnosis treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：